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Abstract  
2019-nCoV is a novel coronavirus was isolated and identified in 2019 in Wuhan, China. On 
17th February and according to world health organization, a number of 71 429 confirmed cases 
worldwide, among them 2162 new cases recorded in the last 24 hours. There is no drug or vaccine 
for human and animal coronavirus. The inhibition of 3CL hydrolase enzyme provides a promising 
therapeutic principle for developing treatments against CoViD-19. The 3CLpro (Mpro) known for 
involving in counteracting the host innate immune response. This work presents the inhibitory effect 
of some natural compounds against 3CL hydrolase enzyme, and explain the main interactions in 
inhibitor-enzyme complex. Molecular docking study carried out using Autodock Vina. By screening 
several molecules, we identified three candidate agents that inhibit the main protease of coronavirus. 
Hispidin, lepidine E, and folic acid bound tightly in the enzyme, strong hydrogen bonds have been 
formed (1.69-1.80Å) with the active site residues. This study provides a possible therapeutic strategy 
for CoViD-19. 
Keywords: Coronavirus, 2019-nCoV protease, CoViD-19, Therapeutic strategy, Antiviral activity, Molecular 
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1. Introduction 
Coronaviruses include a large and diverse family of 
enveloped, positive-stranded RNA viruses [1]. The latest 
International Committee of Taxonomy of Viruses 
(ICTV) classification indicate that the thirty-eight 
species of coronaviruses belong to one of four genera (α-
, β-, δ-, and γ-) [2], where α- and β-CoVs principally 
infect mammals, seventeen species among them hosted 
in bats (BtCoV-HKU10, BtCoV-CDPHE15, BtRfCoV-
HuB13, BtMiCoV-1, BtMiCoV-HKU8, BtMy-Sax11, 
BtNy-Sc13, BtScCoV-512, BtRhCoV-HKU2, 
BtKYNL63, BtHpCoV-ZJ13, MERSr-CoV, BtPiCoV-
HKU5, BtTyCoV-HKU4, BtEoCoV-GCCDC1, 
BtRoCoV-HKU9 and SARSr-CoV), γ- and δ-CoVs 
principally infect birds. Six species of CoVs: α-CoVs 
229E and NL63 and β-CoVs HCoV-HKU1, MERSr-
CoV, SARSr-CoV and HCoV-OC43 can infect human 
causing diseases. [3-6]. SARS-CoV and MERS-CoV 
were the causal agents of respiratory disease outbreaks 
in 2002 and 2012 in Guangdong Province, China, and 
the Middle East, respectively [4,5,7,8]. A novel 
coronavirus was isolated and identified in 2019 in 
Wuhan, China, which was named 2019 novel 
coronavirus (2019-nCoV) [8,9]. 
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On 17th February and according to world health 
organization, a number of 71 429 confirmed cases 
worldwide, among them 2162 new cases recorded in last 
24 hours. 2019-nCoV caused 1772 deaths in china and 3 
death outside [10]. The coronavirus 3CL hydrolase 
(Mpro) enzyme, also known as the main protease, 
exhibits an important function in the viral life-cycle. Its 
inhibition provides a promising therapeutic principle for 
developing treatments against CoViD-19 to prevent 
further spread [11-13]. 
The 3CL hydrolase (Mpro) is one of coronaviruses’ 
proteases. CoVMpro has become an attractive target for 
anti-CoV drug design, due to his responsibility for the 
maturation of itself and key functional enzymes such 
as:replicase and helicase. It is involved in counteracting 
the host innate immune response [14-16]. It has been 
reported that The Mpros of two CoVs infecting pigs 
antagonize the host immune response. They cleave 
porcine IKKγ (NEMO) at the identical site, 
Gln231↓Val232, where NEMO is required for activating 
the NF-κB and IRF3 pathways, which abrogates NF-κB 
signaling and inhibits IFNβ induction [17,18]. the Mpro 
of PDCoV also impair the JAK-STAT pathway by 
processing porcine STAT2 at two sites, Gln685↓Glu686 
and Gln758↓Ser759 [14,19]. 
Hispidin (6-(3,4-dihydroxystyryl)-4-hydroxy-2-
pyrone) is a polyphenol and an important medicinal 
metabolite [20]. It is widespread among fungi of the 
Strophariaceae family, genera Gymnopilus P.karst, 
Hypholoma (Fr.) P.Kumm. and Pholiota (Fr.) P.Kumm. 
[21]. Hispidin was originally isolated as the main 
compound of Inonotus hipidus (Bull.) P.karst from 
Pistacia atlantica tree [22,23]. We have reported in 
previous studies that the isolation method of hispidin, 
and this latter had anti-lipase activity [23-25]. It can be 
found in medicinal mushrooms such as Inonotus and 
Phellinus [26,27]. It has been reported that hispidin 
exhibit antiviral activity [28].  
The seeds of Lepidium sativum are a rich source of 
alkaloids [29]. Lepidine B and E are major compounds 
with 1.1% and 0.88 % respectively. In a previous study, 
it has proved that Lepidine B and E have antimicrobial 
activity [30]. 
Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-
1,6-heptadiene-3,5-dione) is a main phytochemical of 
Curcuma longa L. rhizome (turmeric) [31]. It has been 
demonstrated that curcumin has a wide range of antiviral 
activity against different viruses including inhibitory 
effect of HIV-1 and HIV-2 proteases [31-33]. 
This study aims to identify potent inhibitors for 2019-
nCoV main protease for designing and developing drugs 
against the viral infection. 
 
 
Figure. The role of Main protease in the pathogenic mechanism.
2. Materials and Methods 
2.1 Sequence Alignment of Main protease 
PDB and Sequence files of genomes and main 
protease (6lu7 and 1q2w) was download from the 
Protein Data Bank (PDB) [34-36], where 6lu7 is the 
protein sequence of 2019-nCoV and 1q2w is the protein 
sequence of SARS-CoV. We have conducted a brief 
Alignment of two structures of Mpro: 6lu7 and 1q2w, 
using Similarity Matrix: BLOSUM62, and BioEdit as 
software [37]. 
2.2 Molecular docking 
The inhibitory effect of studied compounds on 3CL 
protease was investigated by blind and specific docking 
experiments. All molecules were obtained from 
PubChem database [38], the 2D structures of studied 
molecules are represented in figure1. The PDB file of the 
enzyme (PDB ID: 6LU7) was download from the Protein 
Data Bank (PDB) [36]. 
 
 
 
Figure1. 2D structure of studied molecules. 
 
 
For docking, the protein must be prepared by 
removing all water molecules, heteroatoms, any 
ligands and co-crystallized solvent. Polar hydrogens 
and partial charges were added to the structure using 
Autodock tools (ADT) (version 1.5.4). Co-crystallized 
inhibitors have been removed. Molecular docking was 
performed by the AutoDock Vina program [39] in an 
eight CPU station. The software uses rectangular 
boxes for the binding site, the center of the box has 
been set and displayed using ADT. The box grid for 
6LU7 in blind and specific docking where sets as 
presented in Table 1 with one Å separated grid points 
positioned in the middle of the active site. The default 
settings were used, except that the number of output 
conformations was set to one. The number of docking 
runs was set at 50 runs. The number of solutions 
obtained is equal to 50 conformations. All these 
solutions are very well handled. The "random seed" is 
random. The preferred conformations were those of 
lower binding energy within the active site. Finally, 
the generated docking results were directly loaded into 
Discovery Studio visualizer, v 4.0 [23,40,41]. 
Table 1. Docking parameters of Target drug (3CL 
hydrolase enzyme PDB ID: 6LU7). 
Molecular 
docking type 
x*y*z Center 
of Grid Box 
x*y*z Size 
of Grid Box 
Blind 
docking 
-26.283*12.602*58.961 52*68*68 
Specific 
docking 
-12.441*12.198*67.681 18*22*24 
3. Results 
3.1. Sequence Alignment of Main protease 
The results are presented in figure 2. 2019-nCoV 
main protease and SARS main protease share 94.80% 
sequence identity at the amino acid level. The genome 
of 2019-nCoV has 89% nucleotide identity with bat 
SARS-like-CoVZXC21 and 82% with that of human 
SARS-CoV [42]. 
 
Figure2. Sequence alignment of 2019-nCoV main protease and SARS-CoV main protease generated in BioEdit. The white 
boxes represent the differences while the gray boxes represent the identity of the two amino acid sequences. 
3.2. Molecular docking 
The results of blind and specific docking for all 
studied molecules with the main protease (3CL 
hydrolase enzyme are summarized in Table 2 and 3, 
respectively.
 
Table 2. The results of blind docking show the main interactions of studied molecules and 2019-nCoV Protease 
(PDB ID: 6LU7). 
Molecule 
Repeating 
ratio % 
Affinity 
(kcal/mol) 
Closest residues Hydrophobic Interactions 
Hydrogen 
bonds 
Length (Å) 
Lepidine B 72 -6.9 
His41, Met49, 
Cys145, Glu166, Pro168 
Π-Alkyl, Π- Π T-
shaped, Π-Sigma 
Glu166 
Glu166 
Gln189 
His163 
3.12 
2.83 
2.95 
2.64 
Lepidine E 76 -7.3 
Thr24, Thr25, Leu27, 
His41, Met49, Cys145 
Π-Alkyl, Π- Π Stacked 
Thr26 
Gly143 
Leu141 
His164 
3.28 
2.97 
1.69 
2.39 
Colchicine 50 -6.3 Asn142, Gln189 - 
Gly143 
Asn142 
3.27 
2.52 
Folic Acid 
 
90 -7.6 Met49, Cys15 Π-Sigma 
Thr24 
Thr25 
Ser46 
Cys145 
His164 
Phe140 
Glu166 
Thr26 
Thr45 
3.02 
2.85 
2.87 
3.00 
2.31 
2.62 
2.10 
2.48 
1.80 
Febuxostat 38 -6.6 
Cys145, Met165, 
Leu167, Pro168, 
Alkyl, Π-Alkyl 
Gly143 
Ser144 
Ser144 
Cys145 
Leu141 
Ser144 
3.12 
2.85 
3.22 
3.06 
2.34 
1.97 
Hispidin 100 -7.2 Cys145, Met165 - 
Ser144 
Cys145 
Leu141 
Ser144 
Met165 
3.01 
3.30 
1.76 
2.74 
2.96 
Aloxistatin 100 -6.3 Met49, His41 Alkyl, Π-Sigma 
His164 
His41 
Gly143 
2.97 
3.28 
3.30 
Curcumin 80 -6.5 Met49, Tyr45, Met165 Π-Alkyl 
Ser144 
Cys145 
Cys145 
3.26 
3.32 
3.34 
DHPEHP 100 -7.2 Cys145, Met165 - 
Arg188 
His163 
Ser144 
Ser144 
Gly143 
2.08 
2.14 
2.39 
2.93 
3.19 
DCMC 
 
86 -6.2 
His41, Tyr54, Met165, 
Glu166, Gln189 
Π-Alkyl, Π-Sigma Arg188 2.28 
FG-7142 84 -6.8 Cys145, Met49 Π-Alkyl 
Glu166 
Asn142 
3.23 
2.65 
Harmaline 100 -6.3 
His41, Met49, 
Met165, 
Alkyl, Π-Alkyl - - 
Harmalol 
38 
 
-5.9 Gly143, Cys145 Π-Alkyl 
Gly143 
Cys145 
His163 
3.28 
3.62 
3.10 
Harmane 98 -6.1 
His41, Cys145, 
Met165 
Alkyl, Π-Alkyl, Π- Π 
T-shaped 
- - 
Harmine 100 -6.3 
His41, Cys145, 
Met165 
Alkyl, Π-Alkyl, Π- Π 
T-shaped 
- - 
Harmol 86 -6.3 His41, Met165 Π-Alkyl - - 
6-
Methoxyharm
alan 
98 -6.3 His41, Met49, Met165 Alkyl, Π-Alkyl - - 
Norharman 70 -5.7 His41, Met165 
Π-Alkyl, Π- Π T-
shaped 
- - 
Pinoline 100 -6.0 
His41, Met165, 
Gln189, 
Π-Alkyl, Π-Sigma, Π- 
Π T-shaped 
Arg188 2.16 
Tetrahydrohar
mine 
78 -6.2 
His41, Met165, 
Gln189 
Π-Alkyl, Π-Sigma Arg188 2.35 
Zk-93426 56 -6.8 
His41, Asn142, 
Cys145, Met49, Met165, 
Glu166 
Alkyl, Π-Alkyl, Π-
Sigma 
Gly143 
Ser144 
Cys145 
3.00 
3.15 
3.16 
Table 3. The results of specific docking show the main interactions of studied molecules and 2019-nCoV Protease (PDB 
ID:6LU7) 
Molecule 
Repeating 
ratio % 
Affinity 
(kcal/mol) 
Closest residues Hydrophobic Interactions 
Hydrogen 
bonds 
Length (Å) 
Lepidine B 90 -7.1 
His41, Met49, Cys145, 
Met165, Gln189 
Π-Alkyl, Π- Π Stacked 
Glu166 
His164 
His163 
3.09 
2.70 
2.90 
Lepidine E 70 -7.8 
Thr25, Leu27, His41, 
Met49, Cys145 
Π-Alkyl, Π-Sigma, Π- 
Π Stacked 
Gly143 
Cys145 
Thr24 
Leu141 
His164 
2.88 
3.38 
2.32 
1.74 
2.38 
Colchicine 100 -6.3 Glu166 - - - 
Folic acid 52 -7.4 
Leu141, Asn142, Gly143, 
Cys145, Glu166, Gln189 
Π-Alkyl 
Thr26 
Glu166 
Thr190 
Ser144 
Cys145 
Gln192 
2.12 
2.13 
1.74 
3.18 
3.13 
2.88 
Febuxostat 100 -6.9 
Cys145, His163, Met165, 
Glu166, Pro168 
Alkyl, Π-Alkyl 
Gly143 
Ser144 
Ser144 
Cys145 
2.97 
2.95 
3.11 
3.08 
Hispidin 100 -7.2 Cys145, Met165 - 
Ser144 
Cys145 
Leu141 
Leu141 
Ser144 
Met165 
3.01 
3.31 
2.83 
1.77 
2.86 
2.93 
Aloxistatin 100 -6.5 His41, His163 Π-Alkyl 
His41 
Gly143 
Ser144 
Glu166 
3.17 
2.95 
3.37 
3.27 
Curcumin 90 -7.5 
His41, Asn142, Cys145, 
Met165 
Π-Alkyl, Π- Π T-
shaped 
Gly143 
Gly143 
Ser144 
Ser144 
3.16 
3.38 
2.96 
3.25 
DHPEHP 100 -7.2 Cys145, Met165, Gln189 - 
Ser144 
Leu141 
Ser144 
3.20 
2.01 
2.68 
DCMC 76 -6.9 Met49, Tyr54, Cys145 Π-Alkyl Ser144 3.19 
FG-7142 100 -6.8 
Cys145, Met49, Phe140, 
Cys145 
Π-Alkyl 
Glu166 
Asn142 
3.21 
2.63 
Harmaline 100 -6.3 His41, Met49, Met165 Alkyl, Π-Alkyl - - 
Harmalol 100 -6.1 Gly143, Cys145 Π-Alkyl 
Gly143 
Cys145 
His163 
2.98 
3.63 
3.02 
Harmane 100 -6.1 His41, Cys145, Met165 
Alkyl, Π-Alkyl, Π- Π 
T-shaped 
- - 
Harmine 100 -6.3 His41, Cys145, Met165 
Alkyl, Π-Alkyl, Π- Π 
T-shaped 
- - 
Harmol 100 -6.3 His41, Met165 
Π-Alkyl, Π- Π T-
shaped, Π-Sigma 
- - 
6-
Methoxyharmal
an 
100 -6.4 His41, Met49, Met165 Alkyl, Π-Alkyl - - 
Norharman 100 -5.7 His41, Met165 
Π-Alkyl, Π- Π T-
shaped 
- - 
Pinoline 100 -5.9 His41, Met165, Gln189 
Π-Alkyl, Π- Π T-
shaped, Π-Sigma 
Arg188 2.14 
Tetrahydrohar
mine 
100 -6.3 
His41, Gln189, Met165, 
Glu166 
Π-Alkyl, Π-Sigma Arg188 2.37 
Zk-93426 82 -6.9 Cys145, Met165, Glu166 Alkyl, Π-Alkyl Glu166 2.73 
 
Figure 3. Binding mode of lepidine B (a), lepidine E (b), folic acid (c), and hispidin (d) at the active site of with 6LU7. Ligand 
are illustrated in gray, rendered as sticks. Different amino acids of the Active site were colored in green. 
4. Discussion 
Chymotrypsin-like protease (3CLpro) called also 
the main protease (Mpro) [43] is suggested to be a 
potential drug target to combat 2019-nCoV. With a 
view to identify inhibitors of 2019-nCoV Mpro, 
twenty-one drugs were selected based on their 
structure and the conformation of Mpro active site. As 
presented in table 2 and 3, the results show that three 
molecules (hispidin, lepidine E and folic acid) could 
bind tightly with the enzyme. His41, Cys145, and 
Glu166 are important residues in the substrate‐binding 
subsite S1 for the proteolytic activity [44], the 
involvement of these residues in forming hydrogen 
bonds is important for the inhibitory effect of the 
Mpro. The molecular docking study demonstrated that 
most of studied molecules bind with one or more of 
these residues. 
The best molecule is hispidin. The blind docking 
shows that 100% of poses are in the active site, those 
poses share the same position and interactions with 
2019-nCoV protease residues (Fig.3 (d)). The 
predicate binding affinity to the 2019-nCoV protease 
is -7.2 Kcal/mol. Hispidin forms a strong hydrogen 
bond network with nCoV-2019 protease, six hydrogen 
bonds have been observed in both blind and specific 
docking. The strongest hydrogen bond (1.77Å) is 
formed by the hydroxyl group of the benzene ring of 
hispidin and CO of Leu141. Hydroxyl groups of 
hispidin and residues Leu141, Ser144, Cys145 and 
Met165 of 2019-nCoV protease form the other 
hydrogen bonds. No hydrophobic interactions have 
been recorded. 
The second molecule is lepidine E, 76% of poses 
are in the active site. We ran specific docking to study 
the binding mode of lepidine E in the active site (Fig.3 
(b)). Lepidine E bind tightly with the 2019-nCoV 
protease residues with a binding affinity -7.8 kcal/mol. 
A very strong and short hydrogen bond has been 
observed between hydroxyl groups of lepidine E and 
Leu141 with length of 1.64Å and 1.74Å in blind 
docking and specific docking respectively. Which 
mean it can form a covalent bond that may lead to 
irreversible inhibition. The other atoms of lepidine E 
forms hydrogen bond with 2019-nCoV protease 
residues, whereas, NH of both imidazole rings bind to 
Oxygen atom (of main chain) of Thr24and His164 
(with interatomic distances “ID” of 2.32 and 2.38Å). 
Oxygen atom and hydroxyl group interact with NH 
main group of Gly143 and Cys145 forming hydrogen 
bond with length of 2.88 and 3.38Å, respectively. This 
binding supported by hydrophobic interactions with 
Thr24, Leu27 and His41 by means Π-sigma, Π-alkyl, 
and Π-Π-stacked, respectively. It is noticed that 
lepidine B bind to 2019-nCoV protease differently, the 
hydrogen bonds are of length 2.7, 2.9 and 3.09Å with 
His164, His163, and Glu166 respectively (Fig.3 (a)). 
The third best molecule is folic acid. The blind 
docking shows that 90% of poses are in the active site 
with a binding affinity of -7.6 kcal/mol. Different 
positions have been recorded in specific docking. 
Despite this, we observe that all positions contain 
hydrogen bonds, from 5 to 11 hydrogen bonds in one 
position. In the most frequented pose, we record 6 
hydrogen bonds (Fig.3 (c)).  The strongest hydrogen 
bond (1.74Å) between this molecule and the protease 
is the carboxyl group of the molecule and the oxygen 
atom of Thr190 in the main chain. The carboxyl group 
of the molecule also forms hydrogen bond with N in 
the side-chain of the residue Gln192 (2.88Å). The 
additional hydrogen bonds are as follows: NH2 of the 
molecule with CO of Thr26, NH with CO of Glu166, 
and N of the pteridine ring of folic acid bind to NH 
main group of Ser144 and Cys145. These hydrogen 
bonds lead to a strong binding of 2019-nCoV protease 
binding site. 
In PDB file of crystal structure of main protease 
with the inhibitor, we observed that the inhibitor was 
bind weaker than our molecules. It forms nine 
hydrogen bonds with 2019n-CoV main protease’s 
residues: Phe140, Gly143, His163, His164, Glu166, 
Gln189, and Thr190. All hydrogen bond’s length was 
higher than 2Å. The shortest hydrogen bond was 
between His163 and PJE5 of the inhibitor with length 
of 2.43Å. 
Curcumin shows also a strong binding affinity with 
-7.5 kcal/mol. In most repeated pose (90%), four 
hydrogen bonds have been formed with Gly143 and 
Ser144 (2.96-3.38 Å). It has been found that curcumin 
has an inhibitory effect against of HIV-1 and HIV-2 
proteases [31-33]. 
Colchicine, febuxostat, aloxistatin, DHPEHP, and 
β-carboline derivatives bind strongly in the binding 
site of 2019-nCoV protease. β-carboline was stabilized 
in the active site mostly by hydrophobic interactions. 
The binding affinity was -6.9 to -5.7 Kcal/mol except 
DHPEHP where the binding affinity was -7.2, but the 
length of the hydrogen bonds was always bigger than 
2Å. No hydrogen bond was formed with colchicine, 
Harmaline, Harmane, Harmine, Harmol, Methoxy, 
and Norharman. 
Since publishing the crystalized structure of 2019-
nCoV main protease, many preprint papers have 
performed insilico studies for identify an inhibitor for 
it. A number of 1903 drugs were tested as the Mpro 
inhibitors in a preprint manuscript, among them, 
Nelfinavir was proposed to be potential inhibitor 
against 2019-nCoV [45]. In another study, it was 
found by screening 8,000 clinical drug libraries that 4 
small molecular drugs have high binding capacity with 
the main protease [46]. No binding manner or 
hydrogen bonds formation with active site residues has 
been discussed in these studies. It was declared that 10 
commercial medicines may form hydrogen bonds with 
key residues of 2019-nCoV main protease [47]. 
According to articles published in Nature 
Communications and Nature reviews drug 
discovery (Sheahan et al, 2020 and Guangdi et al, 
2020) [48,49], currently, only four drugs 
(Ritonavir, Darunavir, cobicistat, and ASC09F) are 
considered for treatment of 2019-nCoV as 3CLpro 
inhibitors. Through this study, we recommend to 
enter these molecules (Hispidin, Lepidine E and 
Folic acid) in the therapy of this disease especially 
that the studied molecules are known and all the 
necessary clinical experiments are already done, 
for the natural compounds, they are used in folk 
medicine to treat several diseases. 
1 Conclusions 
We have found that hispidin, lepidine E, and folic 
acid display a strong inhibitory activity on 3CL 
enzyme, which prevents spreading the infection by 
stopping the virus’s cycle life. Based on this study's 
results and other previous studies, we propose a 
therapeutic strategy to prevent and treat the virus 
infection. The potent metabolites hispidin and folic 
acid that inhibits the main protease of 2019-nCoV 
might be an effective strategy to treat 2019 novel 
coronavirus infected individuals. Those natural 
molecules also might become drug candidates as anti- 
CoViD-19 drug. 
LIST OF ABBREVIATIONS 
2019-nCoV: 2019 novel coronavirus (the virus) 
3CL hydrolase: 3-chymotrypsin-like hydrolase 
CoViD-19: coronavirus disease 2019 (the illness) 
MERS: Middle East respiratory syndrome 
Mpro: Main protease 
SARS: Severe acute respiratory syndrome 
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